Literature DB >> 28444220

A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies.

Marie Coutelier1,2,3,4,5,6, Giulia Coarelli1,2,3,4,7, Marie-Lorraine Monin7, Juliette Konop1,2,3,4,6, Claire-Sophie Davoine1,2,3,4, Christelle Tesson1,2,3,4,6, Rémi Valter1,2,3,4,6, Mathieu Anheim8,9,10, Anthony Behin11, Giovanni Castelnovo12, Perrine Charles7, Albert David13, Claire Ewenczyk7, Mélanie Fradin14,15, Cyril Goizet16,17, Didier Hannequin18, Pierre Labauge19, Florence Riant20, Pierre Sarda21, Yves Sznajer22, François Tison23, Urielle Ullmann24, Lionel Van Maldergem25,26, Fanny Mochel1,2,3,4,7,27, Alexis Brice1,2,3,4,7, Giovanni Stevanin1,2,3,4,6,7, Alexandra Durr1,2,3,4,7.   

Abstract

Autosomal dominant cerebellar ataxias have a marked heterogeneous genetic background, with mutations in 34 genes identified so far. This large amount of implicated genes accounts for heterogeneous clinical presentations, making genotype-phenotype correlations a major challenge in the field. While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more 'conventional' ataxias. After exclusion of CAG/polyglutamine expansions in spinocerebellar ataxia genes in 412 index cases with dominantly inherited cerebellar ataxias, we aimed to establish the relative frequencies of mutations in other genes, with an approach combining panel sequencing and TaqMan® polymerase chain reaction assay. We found relevant genetic variants in 59 patients (14.3%). The most frequently mutated were channel genes [CACNA1A (n = 16), KCND3 (n = 4), KCNC3 (n = 2) and KCNA1 (n = 2)]. Deletions in ITPR1 (n = 11) were followed by biallelic variants in SPG7 (n = 9). Variants in AFG3L2 (n = 7) came next in frequency, and variants were rarely found in STBN2 (n = 2), ELOVL5, FGF14, STUB1 and TTBK2 (n = 1 each). Interestingly, possible risk factor variants were detected in SPG7 and POLG. Clinical comparisons showed that ataxias due to channelopathies had a significantly earlier age at onset with an average of 24.6 years, versus 40.9 years for polyglutamine expansion spinocerebellar ataxias and 37.8 years for SPG7-related forms (P = 0.001). In contrast, disease duration was significantly longer in the former (20.5 years versus 9.3 and 13.7, P=0.001), though for similar functional stages, indicating slower progression of the disease. Of interest, intellectual deficiency was more frequent in channel spinocerebellar ataxias, while cognitive impairment in adulthood was similar among the three groups. Similar differences were found among a single gene group, comparing 23 patients with CACNA1A expansions (spinocerebellar ataxia 6) to 22 patients with CACNA1A point mutations, which had lower average age at onset (25.2 versus 47.3 years) with longer disease duration (18.7 versus 10.9), but lower severity indexes (0.39 versus 0.44), indicating slower progression of the disease. In conclusion, we identified relevant genetic variations in up to 15% of cases after exclusion of polyglutamine expansion spinocerebellar ataxias, and confirmed CACNA1A and SPG7 as major ataxia genes. We could delineate firm genotype-phenotype correlations that are important for genetic counselling and of possible prognostic value.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CACNA1A; SPG7; cerebellar ataxia; channelopathies

Mesh:

Substances:

Year:  2017        PMID: 28444220     DOI: 10.1093/brain/awx081

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

Review 1.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

Review 2.  Clinical application of next generation sequencing in hereditary spinocerebellar ataxia: increasing the diagnostic yield and broadening the ataxia-spasticity spectrum. A retrospective analysis.

Authors:  Daniele Galatolo; Alessandra Tessa; Alessandro Filla; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2017-12-06       Impact factor: 2.660

Review 3.  Spinocerebellar ataxia type 48: last but not least.

Authors:  Giovanna De Michele; Daniele Galatolo; Melissa Barghigiani; Diletta Dello Iacovo; Rosanna Trovato; Alessandra Tessa; Elena Salvatore; Alessandro Filla; Giuseppe De Michele; Filippo M Santorelli
Journal:  Neurol Sci       Date:  2020-04-27       Impact factor: 3.307

Review 4.  Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2.

Authors:  Polina A Egorova; Ilya B Bezprozvanny
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

5.  Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with SPG7.

Authors:  Giulia Coarelli; Rebecca Schule; Bart P C van de Warrenburg; Peter De Jonghe; Claire Ewenczyk; Andrea Martinuzzi; Matthis Synofzik; Elisa G Hamer; Jonathan Baets; Mathieu Anheim; Ludger Schöls; Tine Deconinck; Pegah Masrori; Bertrand Fontaine; Thomas Klockgether; Maria Grazia D'Angelo; Marie-Lorraine Monin; Jan De Bleecker; Isabelle Migeotte; Perrine Charles; Maria Teresa Bassi; Thomas Klopstock; Fanny Mochel; Elisabeth Ollagnon-Roman; Marc D'Hooghe; Christoph Kamm; Delia Kurzwelly; Melanie Papin; Claire-Sophie Davoine; Guillaume Banneau; Sophie Tezenas du Montcel; Danielle Seilhean; Alexis Brice; Charles Duyckaerts; Giovanni Stevanin; Alexandra Durr
Journal:  Neurology       Date:  2019-05-08       Impact factor: 9.910

6.  Channelopathies Are a Frequent Cause of Genetic Ataxias Associated with Cerebellar Atrophy.

Authors:  Laurence Gauquelin; Taila Hartley; Mark Tarnopolsky; David A Dyment; Bernard Brais; Michael T Geraghty; Martine Tétreault; Sohnee Ahmed; Samantha Rojas; Karine Choquet; Jacek Majewski; François Bernier; Allan Micheil Innes; Guy Rouleau; Oksana Suchowersky; Kym M Boycott; Grace Yoon
Journal:  Mov Disord Clin Pract       Date:  2020-09-29

7.  Novel De Novo KCND3 Mutation in a Japanese Patient with Intellectual Disability, Cerebellar Ataxia, Myoclonus, and Dystonia.

Authors:  Masanori Kurihara; Hiroyuki Ishiura; Takuya Sasaki; Juuri Otsuka; Toshihiro Hayashi; Yasuo Terao; Takashi Matsukawa; Jun Mitsui; Juntaro Kaneko; Kazutoshi Nishiyama; Koichiro Doi; Jun Yoshimura; Shinichi Morishita; Jun Shimizu; Shoji Tsuji
Journal:  Cerebellum       Date:  2018-04       Impact factor: 3.847

8.  Efficacy of Exome-Targeted Capture Sequencing to Detect Mutations in Known Cerebellar Ataxia Genes.

Authors:  Marie Coutelier; Monia B Hammer; Giovanni Stevanin; Marie-Lorraine Monin; Claire-Sophie Davoine; Fanny Mochel; Pierre Labauge; Claire Ewenczyk; Jinhui Ding; J Raphael Gibbs; Didier Hannequin; Judith Melki; Annick Toutain; Vincent Laugel; Sylvie Forlani; Perrine Charles; Emmanuel Broussolle; Stéphane Thobois; Alexandra Afenjar; Mathieu Anheim; Patrick Calvas; Giovanni Castelnovo; Thomas de Broucker; Marie Vidailhet; Antoine Moulignier; Robert T Ghnassia; Chantal Tallaksen; Cyril Mignot; Cyril Goizet; Isabelle Le Ber; Elisabeth Ollagnon-Roman; Jean Pouget; Alexis Brice; Andrew Singleton; Alexandra Durr
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

Review 9.  Molecular genetic testing for hereditary ataxia: What every neurologist should know.

Authors:  Stephanie E Wallace; Thomas D Bird
Journal:  Neurol Clin Pract       Date:  2018-02

10.  Novel KCND3 Variant Underlying Nonprogressive Congenital Ataxia or SCA19/22 Disrupt KV4.3 Protein Expression and K+ Currents with Variable Effects on Channel Properties.

Authors:  Ginevra Zanni; Chen-Tsung Hsiao; Ssu-Ju Fu; Chih-Yung Tang; Alessandro Capuano; Luca Bosco; Federica Graziola; Emanuele Bellacchio; Serenella Servidei; Guido Primiano; Bing-Wen Soong; Chung-Jiuan Jeng
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.